Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RLF

Gene summary for RLF

Gene summary.

Gene information	Species	Human
	Gene symbol	RLF
	Gene ID	6018
	Gene name	RLF zinc finger
	Gene Alias	ZN-15L
	Cytomap	1p34.2
	Gene Type	protein-coding
	GO ID	GO:0006139
	UniProtAcc	Q13129

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6018	RLF	GSM5353240_PA_PR5254_T1_S15_L001	Human	Prostate	Tumor	2.74e-02	2.34e-01	0.1575
6018	RLF	GSM5353243_PA_PR5261_T1_S23_L002	Human	Prostate	Tumor	6.18e-07	3.44e-01	0.1545
6018	RLF	GSM5353244_PA_PR5261_T2_S24_L002	Human	Prostate	Tumor	1.12e-03	1.79e-01	0.1569
6018	RLF	P1_S1_AK	Human	Skin	AK	5.56e-27	6.67e-01	-0.3399
6018	RLF	P2_S3_AK	Human	Skin	AK	1.37e-20	5.70e-01	-0.3287
6018	RLF	P2_S4_SCCIS	Human	Skin	SCCIS	2.12e-17	4.53e-01	-0.3043
6018	RLF	P3_S6_AK	Human	Skin	AK	9.91e-11	4.66e-01	-0.3256
6018	RLF	P4_S8_cSCC	Human	Skin	cSCC	6.16e-15	3.63e-01	-0.3095
6018	RLF	P5_S10_cSCC	Human	Skin	cSCC	2.04e-09	3.10e-01	-0.299
6018	RLF	P1_cSCC	Human	Skin	cSCC	9.99e-03	1.80e-01	0.0292
6018	RLF	P2_cSCC	Human	Skin	cSCC	2.74e-03	8.55e-02	-0.024
6018	RLF	P4_cSCC	Human	Skin	cSCC	3.62e-03	1.64e-01	-0.00290000000000005
6018	RLF	P10_cSCC	Human	Skin	cSCC	1.69e-12	4.36e-01	0.1017

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00165705	Cervix	CC	histone modification	84/2311	463/18723	1.70e-04	2.01e-03	84
GO:00349685	Cervix	CC	histone lysine methylation	27/2311	115/18723	6.61e-04	6.09e-03	27
GO:00510528	Cervix	CC	regulation of DNA metabolic process	65/2311	359/18723	9.25e-04	7.84e-03	65
GO:00165715	Cervix	CC	histone methylation	30/2311	141/18723	1.88e-03	1.39e-02	30
GO:00180224	Cervix	CC	peptidyl-lysine methylation	28/2311	131/18723	2.43e-03	1.71e-02	28
GO:00064795	Cervix	CC	protein methylation	36/2311	181/18723	2.46e-03	1.71e-02	36
GO:00082135	Cervix	CC	protein alkylation	36/2311	181/18723	2.46e-03	1.71e-02	36
GO:00182054	Cervix	CC	peptidyl-lysine modification	62/2311	376/18723	1.04e-02	4.97e-02	62
GO:001657015	Esophagus	ESCC	histone modification	323/8552	463/18723	2.61e-26	7.88e-24	323
GO:001820514	Esophagus	ESCC	peptidyl-lysine modification	259/8552	376/18723	3.90e-20	5.26e-18	259
GO:004477216	Esophagus	ESCC	mitotic cell cycle phase transition	281/8552	424/18723	4.63e-18	4.45e-16	281
GO:005105215	Esophagus	ESCC	regulation of DNA metabolic process	232/8552	359/18723	2.40e-13	1.13e-11	232
GO:0016049110	Esophagus	ESCC	cell growth	289/8552	482/18723	1.29e-10	3.77e-09	289
GO:00434143	Esophagus	ESCC	macromolecule methylation	199/8552	316/18723	3.44e-10	9.57e-09	199
GO:00322592	Esophagus	ESCC	methylation	222/8552	364/18723	2.26e-09	5.09e-08	222
GO:000155819	Esophagus	ESCC	regulation of cell growth	248/8552	414/18723	2.97e-09	6.45e-08	248
GO:000008214	Esophagus	ESCC	G1/S transition of mitotic cell cycle	134/8552	214/18723	4.04e-07	5.55e-06	134
GO:004484314	Esophagus	ESCC	cell cycle G1/S phase transition	148/8552	241/18723	5.68e-07	7.48e-06	148
GO:000647914	Esophagus	ESCC	protein methylation	115/8552	181/18723	9.07e-07	1.16e-05	115
GO:000821314	Esophagus	ESCC	protein alkylation	115/8552	181/18723	9.07e-07	1.16e-05	115

Page: 1 2 3 4 5 6

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RLF

SNV

Missense_Mutation

novel

c.1436N>A

p.Cys479Tyr

p.C479Y

Q13129

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

RLF

SNV

Missense_Mutation

c.5122G>C

p.Glu1708Gln

p.E1708Q

Q13129

protein_coding

tolerated(0.22)

benign(0.234)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RLF

SNV

Missense_Mutation

c.3224N>T

p.Ser1075Leu

p.S1075L

Q13129

protein_coding

deleterious(0.02)

benign(0.015)

TCGA-AC-A6IX-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

RLF

SNV

Missense_Mutation

rs752951336

c.2308C>T

p.Arg770Cys

p.R770C

Q13129

protein_coding

deleterious(0.01)

possibly_damaging(0.854)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RLF

SNV

Missense_Mutation

rs368064385

c.4372C>T

p.Arg1458Cys

p.R1458C

Q13129

protein_coding

tolerated(0.19)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RLF

SNV

Missense_Mutation

c.388N>C

p.Val130Leu

p.V130L

Q13129

protein_coding

tolerated(0.07)

benign(0.027)

TCGA-AN-A0AT-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

RLF

SNV

Missense_Mutation

c.2606A>G

p.Asp869Gly

p.D869G

Q13129

protein_coding

tolerated(0.09)

benign(0.015)

TCGA-B6-A0I6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

RLF

SNV

Missense_Mutation

c.2264C>T

p.Ser755Leu

p.S755L

Q13129

protein_coding

deleterious(0)

possibly_damaging(0.761)

TCGA-B6-A0IK-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

RLF

SNV

Missense_Mutation

c.2222N>T

p.Pro741Leu

p.P741L

Q13129

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

RLF

SNV

Missense_Mutation

c.5612N>A

p.Cys1871Tyr

p.C1871Y

Q13129

protein_coding

deleterious(0)

probably_damaging(0.956)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1